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Abstract
Background: Development of resistance against first line drug therapy including cisplatin and paclitaxel in high-
grade serous ovarian cancer (HGSOC) presents a major challenge. Identifying drug candidates breaking resistance,
ideally combined with predictive biomarkers allowing precision use are needed for prolonging progression free
survival of ovarian cancer patients.
Modeling of molecular processes driving drug resistance in tumor tissue further combined with mechanism of
action of drugs provides a strategy for identification of candidate drugs and associated predictive biomarkers.
Results: Consolidation of transcriptomics profiles and biomedical literature mining results provides 1242 proteins
linked with ovarian cancer drug resistance. Integrating this set on a protein interaction network followed by graph
segmentation results in a molecular process model representation of drug resistant HGSOC embedding 409 proteins in
24 molecular processes. Utilizing independent transcriptomics profiles with follow-up data on progression free survival
allows deriving molecular biomarker-based classifiers for predicting recurrence under first line therapy. Biomarkers of
specific relevance are identified in a molecular process encapsulating TGF-beta, mTOR, Jak-STAT and Neurotrophin
signaling. Mechanism of action molecular model representations of cisplatin and paclitaxel embed the very same
signaling components, and specifically proteins afflicted with the activation status of the mTOR pathway become
evident, including VEGFA. Analyzing mechanism of action interference of the mTOR inhibitor sirolimus shows specific
impact on the drug resistance signature imposed by cisplatin and paclitaxel, further holding evidence for a synthetic
lethal interaction to paclitaxel mechanism of action involving cyclin D1.
Conclusions: Stratifying drug resistant high grade serous ovarian cancer via VEGFA, and specifically treating with
mTOR inhibitors in case of activation of the pathway may allow adding precision for overcoming resistance to first
line therapy.
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Background
Development of drug resistance represents a major
challenge in cancer therapy. In case of high-grade ser-
ous ovarian cancer (HGSOC), accounting for 60–80 %
of epithelial ovarian carcinoma, initial sensitivity to
standard platinum-based therapy is around 80 %. How-
ever, relapse rates in more advanced stages reach up to
70 %, with a first appearance varying from a few
months to more than 5 years [1, 2]. In clinical practice
a combination with a second drug, mainly taxanes is
administered [3]. The benefit in terms of progression
free survival of this combination is controversially
discussed, but at least toxicity is reduced compared to
monotherapy [4]. Further clinical trials have been con-
ducted utilizing drugs for specifically targeting platinum-
resistant tumors, but overall response rates were found in
a low range of 5–20 % [2].
Several molecular mechanisms leading to drug resist-
ance, being generic across drug classes or specific for a
selected drug are described [5]. A prominent factor is in-
creased drug efflux via ABC transporter expression [6].
Other mechanisms limiting drug effect involve modifying
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the drug or its targets. Examples include formation of
glutathione-drug conjugates or expression of tubulin
isotypes limiting efficiency of microtubule targeting drugs
[7, 8]. Altered downstream effects by e.g. up-regulation of
DNA repair mechanisms or anti-apoptotic pathways are a
further class of events seen in drug resistance [9]. Deregu-
lation of entire signaling pathways like PI3K-Akt/mTOR
are reported as being involved in resistance to antineo-
plastic agents in a number of tumors [10]. On such back-
ground of multiple molecular components individually or
in combination contributing to drug resistance, identifica-
tion of resistance hub functionality on a molecular process
level promises optimal targets for halting multiple drug
resistance paths. Such strategy demands a systematic inte-
gration of the individual resistance contributors into a
molecular mechanistic representation of a drug resistant
clinical phenotype.
With the advent of omics profiling explorative ana-
lysis of large sets of molecular features associated with
disease development and progression became feasible.
Generic analysis of omics datasets focuses on identifi-
cation of individual molecular features exhibiting sig-
nificant differences in abundance e.g. in case-control
studies [11]. More recent approaches have comple-
mented statistics-driven approaches with biological
background knowledge e.g. in the form of protein-
protein interaction data [12] aiming at expanding from
molecular feature association towards identification of
molecular mechanistic context. These strategies allow
building descriptive molecular models of disease patho-
physiology on the level of molecular processes and path-
ways [13, 14]. Specifically in oncology research various
types of biological network models have been used to
model pathophysiology, but also to identify and prioritize
drug targets and molecular markers [15]. As example,
association of differentially expressed genes in a set of hu-
man cancer cell lines resistant to methotrexate have been
analyzed on a biological network level by Selga and col-
leagues, allowing identification of resistance-associated
key proteins [16]. In a similar way network-based models
approximating drug mechanism of action at the interface
of disease molecular mechanisms have been introduced
[17, 18]. In contrast to targeting individual molecular
features involved in development of drug resistance
such network-based approaches promise identification
of more generic, underlying signaling components, in
consequence improving coverage of individual resist-
ance effector mechanisms.
In this work we present a HGSOC molecular process
model resting on an interaction network of molecular
features associated with platinum-based drug resistance
as identified in transcriptomics studies, further comple-
mented with protein coding genes mined from scien-
tific publications. We use this model representation to
identify core molecular processes afflicted with drug re-
sistance specifically triggered by a combination therapy
of platinum-based drugs and taxanes. With such drug
resistance molecular processes as basis, screening for
drug targets, drug mechanism of action interference
and predictive biomarker candidates becomes feasible.
Methods
A data analysis overview is depicted in Fig. 1 with indi-
vidual analysis steps and results described in the follow-
ing sections.
Molecular data sources characterizing drug resistant
HGSOC
Protein coding genes associated with drug resistant high-
grade serous ovarian cancer were retrieved by querying the
scientific literature, further extended by including results
from transcriptomics studies. For mining scientific litera-
ture the following NCBI PubMed query was executed:
(“Ovarian Neoplasms/genetics” [majr]) OR (“Ovarian Neo-
plasms/pathology” [majr]) OR (“Ovarian Neoplasms/physio-
pathology” [majr]) OR (“Ovarian Neoplasms/enzymology”
[majr]) OR (“Ovarian Neoplasms/chemistry” [majr]) OR
(“Ovarian Neoplasms/metabolism” [majr]) AND (“recurren-
ce”[mesh] OR “prognosis”[mesh] OR “drug resistance, neo-
plasm” [mh]) AND “humans” [mh]. 5663 publications were
identified and used to retrieve gene annotation provided by
NCBI gene2pubmed, resulting in 777 unique human pro-
tein coding genes (LIT-HGSOC dataset).
This set of literature-based molecular features was
complemented by protein coding genes derived from
two transcriptomics studies in focus of disease relapse
under platinum-based drug therapy. A first set of 432
molecular features was extracted from a study per-
formed by Helleman et al., presenting a meta-analysis of
nine individual transcriptomics studies, all focusing on
HGSOC relapse in the context of platinum-based drug
therapy (TX-HELLEMAN dataset) [19]. A second set of
100 molecular features was extracted from the cancer
genome atlas providing a study on HGSOC published by
Verhaak et al. [20] also focusing on cancer relapse under
platinum-based drug therapy (TX-VERHAAK dataset).
An overview of used datasets within this study is avail-
able in Table 1.
Finally, the three molecular feature sets LIT-HGSOC,
TX-HELLEMAN, and TX-VERHAAK were combined
into a set of 1,242 unique protein coding genes.
Deriving a high-grade serous ovarian cancer resistance
(HGSOCr) molecular model
Consolidated molecular features associated with drug resist-
ant HGSOC were mapped on a hybrid interaction network
including protein-protein interaction data from IntAct, Bio-
Grid, and Reactome together with computationally inferred
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relations [21]. 1202 out of 1242 molecular features of the re-
sistance molecular feature set could be assigned as nodes on
the given network holding in total 15,905 protein coding
genes. Subsequently, the HGSOCr specific induced subgraph
was extracted, including all molecular features from the
signature also holding an interaction to at least one other
feature of the resistance molecular feature set. The induced
subgraph, consisting of 1,062 protein coding genes, was for-
warded to the Molecular Complex Detection algorithm for
identifying clusters of nodes, in the following denoted as
Fig. 1 Data analysis workflow. Schematic representation of the data analysis workflow with used datasets, methods, and results indicated by grey,
white, and green boxes respectively
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molecular processes [22, 23]. Including network interaction
data between nodes across molecular processes forms a mo-
lecular model representation of drug resistant high grade ser-
ous ovarian cancer. This molecular model representation is
composed of 24 individual molecular processes, each holding
a set of highly interconnected proteins, embedding in total
409 proteins.
Drug mechanism of action (MoA) molecular model
computation and interference analysis with the HGSOCr
molecular model
Cisplatin and paclitaxel are selected as representative
compounds for platinum-based and taxane-based ther-
apies, respectively. Drug mechanism of action molecular
models were generated for these two compounds follow-
ing the procedure applied for deriving the HGSOCr
molecular model. Molecular feature sets characterizing
drug effect were retrieved via gene2pubmed feature as-
signments to publications identified with the PubMed
query Cisplatin[mh] (LIT-CISPLATIN dataset) and Pacli-
taxel[mh] (LIT-PACLITAXEL dataset), respectively. An
additional drug MoA molecular model was derived for the
mTOR inhibitor sirolimus applying the PubMed query
Sirolimus[mh] (LIT-SIROLIMUS dataset).
Interference of a drug MoA molecular model and
the HGSOCr molecular model is determined as num-
ber of molecular features being part of the respective
drug MoA molecular model as well as being part of
the HGSOCr molecular model.
Pathway enrichment, activation status analysis and
synthetic lethal interactions
Molecular pathway enrichment analysis using the Data-
base for Annotation, Visualization and Integrated Dis-
covery (DAVID) tool [24] was conducted for selected
processes of the HGSOCr molecular model. The KEGG
set of molecular pathways was used as underlying path-
way resource, p-values were adjusted for multiple testing
using the Benjamini-Hochberg correction method.
The transcriptomics dataset from Ferriss et al. [25] was
used for evaluating the status of molecular pathways iden-
tified in enrichment analysis. The expression profiles were
retrieved from the Gene Expression Omnibus (GEO)
(GSE30161) and processed using the affy R package apply-
ing robust multiarray average (RMA) normalization (TX-
FERRISS). Only patients with serous ovarian cancer were
included in the calculations. Correlations in gene expres-
sion of pathway members to progression free survival
were calculated in order to verify pathway relevance in
drug resistance.
Synthetic lethal interactions of protein coding genes em-
bedded in drug mechanism of action molecular models
were retrieved from BioGRID. Interactions with experi-
mental evidence tags “Synthetic Lethality” or “Negative
Genetic” for the organisms Homo sapiens, Saccharomyces
cerevisiae, Mus musculus, Gallus gallus, Caenorhabditis
elegans, and Drosophila melanogaster were included.
Orthology mapping from non-human model organisms to
the corresponding human genes were based on orthology
information as provided by Ensembl.
Table 1 Listing of used transcriptomics and literature mining datasets
Dataset
acronym
Dataset description Dataset use Ref
LIT-HGSOC Set of molecular features linked to HGSOC via literature mining. Input for generating the
HGSOCr molecular model
–
TX-HELLEMAN Meta-analysis of nine transcriptomics studies reporting differentially regulated genes
associated with ovarian cancer relapse.
Input for generating the
HGSOCr molecular model
[19]
TX-VERHAAK Transcriptomics dataset from The Cancer Genome Atlas reporting on differentially
expressed genes linked with ovarian cancer disease prognosis.
Input for generating the
HGSOCr molecular model
[20]
TX-FERRISS Transcriptomics study on ovarian cancer patients to identify predictors of platinum
resistance.
Input for evaluating the status of
mTOR signaling pathway members
[25]
TX-TOTHILL Transcriptomics study involving more than 200 ovarian cancer patients in order to
identify molecular signature for subtyping ovarian cancer.
Training set for deriving the
prognostic transcript panel
[26]
TX-YOSHIHARA Transcriptomics study to identify survival signatures in serous ovarian cancer patients. Test set for validating the
prognostic transcript panel
[27]
LIT-CISPLATIN Set of molecular features linked to cisplatin via literature mining. Input for generating the cisplatin
MoA molecular model
–
LIT-PACLITAXEL Set of molecular features linked to paclitaxel via literature mining. Input for generating the paclitaxel
MoA molecular model
–
LIT-SIROLIMUS Set of molecular features linked to sirolimus via literature mining. Input for generating the sirolimus
MoA molecular model
–
Overview and short description of datasets used for the integrated analysis in the present study. The specific use of the dataset in the integrated analysis is given
along with the link to original publications for transcriptomics datasets
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Prognostic biomarkers included in the HGSOCr molecular
model feature set
Two transcriptomics datasets, TX-TOTHILL and TX-
YOSHIHARA, not included in deriving the HGSOCr mo-
lecular model were used in order to evaluate the prognostic
potential (time to relapse) of molecular features embedded
in the HGSOCr molecular model. Raw transcriptomics data
files were retrieved from GEO for the studies of Tothill et
al. (GSE9899, TX-TOTHILL dataset) [26] and Yoshihara et
al. (GSE17260, TX-YOSHIHARA dataset) [27] together
with data on time of progression free survival (PFS) as
provided. Both studies focused on patients undergoing
standard chemotherapy using platinum-based drugs in
combination with taxanes. Pearson correlation coefficients
of candidate biomarker expression levels and PFS given
months were computed. Additionally, dichotomization was
performed for allowing computation of area under the
curve (AUC) values. For this, patients with PFS of less than
12 months were classified as the drug resistance cohort.
The platinum based first line therapy takes 6 months and
relapse within 6 months after the end of treatment is re-
ferred to as therapy resistance (12 months in total). Patients
with PFS of more than 22 months were considered sensi-
tive to chemotherapy. We focused on these two extremes
thus excluding patient only partially responding to therapy
in order to get a clearer picture on deregulated processes
and markers. For the TX-TOTHILL dataset only patients
with serous ovarian cancer treated with a platinum based
therapy were included. 82 of the 226 patients had PFS of
less than 12 months and 63 of the 226 patients had PFS of
more than 22 months. The TX-YOSHIHARA dataset
consists of 110 patients, all of being of type serous
ovarian cancer and receiving platinum based therapy.
29 patients had PFS of less than 12 months and 45 had
PFS of more than 22 months.
For retrieving expression profiles of resistant and sensi-
tive patient cohorts the Affymetrix microarray data from
TX-TOTHILL were processed using the affy R package
applying RMA normalization.
For the Agilent-based data set TX-YOSHIHARA the
R limma package was used for data preparation with
the normexp background correction method and
quantile normalization, averaging duplicate features
after normalization.
The dataset TX-TOTHILL was used as training data-
set in order to delineate a biomarker panel for assessing
outcome on the level of progression free survival
categorization. The dataset TX-YOSHIHARA was suc-
cessively used as test dataset for the transcript feature
panel delineated from the TX-TOTHILL dataset. Boot-
strapping (200 runs) of least absolute shrinkage and se-
lection operator (LASSO) logistic models was performed
to calculate feature selection frequencies thus estimating
individual feature relevance. The tuning parameter λ was
selected in order to minimize cross-validation deviance.
To assess the performance of the transcript feature panel
an optimism adjusted area under the curve (AUCadj)
value for a logistic model only using features from the
transcript feature panel as explanatory variables was
calculated for each of the two datasets with AUCadj =
AUCobs – (AUCboot – AUCtest), where AUCobs is the
training AUC achieved on the entire dataset, AUCboot is
the training AUC achieved on the bootstrapped data set
and AUCtest is the AUC of a predictor trained on the
bootstrapped data set tested on the entire data set. All cal-
culations were done in R using the packages GLMNET
and ROC.
For annotation of biomarker candidates regarding
evidence for being on a protein level detectable in circu-
lation the following criteria were applied: (i) being iden-
tified as secreted or in the extracellular space based on
UniProt subcellular localization annotation, (ii) being
reported as measurable in blood based on NCBI pubmed
MeSH annotation of any disease term with the MeSH
qualifier blood, or (iii) being reported as biomarker in
ovarian cancer based on publications annotated with the
MeSH terms (ovarian neoplasms[majr] AND (biological
markers[mh] OR tumor markers, biological[mh])).
Results
Molecular representation of HGSOC resistance
The scientific literature search provides 777 molecular fea-
tures associated with HGSOC resistance (LIT-HGSOC).
Together with 432 features from the transcriptomics meta-
study TX-HELLEMAN and 100 features as reported by
Verhaak et al. (TX-VERHAAK), a unique set of 1242
molecular features is identified as associated with drug re-
sistant HGSOC. Apparent is the minor overlap of the indi-
vidual data sets, a frequent finding in data source assembly
across source types [28], but also in comparative analysis of
signatures generated in the same omics category as tran-
scriptomics [29]. Data integration on interaction networks
allows identifying a connected core feature set, which based
on adding interactions includes a biological constraint on
top of varying evidence of the features identified in individ-
ual experimental settings [30].
Mapping the HGSOCr feature set on the selected
hybrid interaction network results in an induced sub-
graph holding 1062 protein nodes. This subgraph resem-
bles one giant component with a path from each protein
coding gene (network node) to all other gene nodes. Ap-
plying a segmentation algorithm for identifying densely
connected gene sets provides 24 molecular process seg-
ments holding in total 409 molecular features, with mo-
lecular process size ranging from 3 to 95 nodes (Fig. 2a).
Apparent is a significant reduction of the number of
protein coding genes being included in the model repre-
sentation, reflecting the interaction-based filtering of the
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initial feature set on the network level. Regarding rela-
tive contributions from the initial data sources 304 fea-
tures in the molecular model link back to scientific
literature, complemented by 138 features stemming from
transcriptomics studies. Assuming improved evidence
for representation of relevant mechanistic context on
such molecular process level this molecular model rep-
resentation and embedded protein coding genes are used
in further analysis.
A transcript feature set for tumor relapse prognosis
Forwarding the 409 protein coding genes of the mo-
lecular model to a LASSO logistic model for class pre-
diction of sensitive and resistant samples according to
profiling data of TX-TOTHILL (Table 2) provides a
panel of 15 transcripts. The classifier achieves an opti-
mism corrected AUC of 0.786 with the largest contri-
bution of transcript features coming from molecular
process 4 (Fig. 2), namely the nuclear receptor coacti-
vator 3 (NCOA3), the transcription factor SPDEF, the
transforming growth factor beta 2 (TGFB2) and the
insulin-like growth factor 1 (IGF1). Next to represen-
tatives from molecular process 4 further transcripts
included in the panel are the ephrin receptor 4
(EPHB4) from molecular process 1, the homeodomain
interacting protein kinase 2 (HIPK2) and the forkhead box
J1 (FOXJ1) from molecular process 2, the transcription fac-
tor TCF7L2, the phosphatase and tensin homolog (PTEN)
and the homeobox 5 (HOXA5) from molecular process 3,
a DNA replication licensing factor (MCM4) from molecu-
lar process 5, and the prostaglandin-endoperoxide synthase
2 (PTGS2) and the cyclin-dependent kinase inhibitor 1C
(CDKN1C) from molecular process 6, complemented by
the ELAV like RNA binding protein 1 (ELAVL1) and the
chemokine (C-X-C motif) ligand 12 (CXCL12) from mo-
lecular processes 10 and 11, respectively.
This classifier holding 15 transcripts was evaluated in the
independent transcriptomics dataset TX-YOSHIHARA,
reaching an optimism corrected AUC value of 0.721.
Evaluating selection probabilities of biomarkers ac-
cording to the LASSO procedure identified biomarker
candidates associated with molecular process 4 as most
relevant in both, training and test datasets for linking
with relapse.
Cisplatin and paclitaxel MoA molecular models and
interference with the HGSOCr molecular process 4
According to data inclusion criteria the HGSOCr mo-
lecular model rests explicitly on molecular features
identified in the context of resistance to standard
chemotherapy utilizing platinum-based drugs together
with taxanes. As molecular process 4 holds key bio-
markers for adding to an explanation of variance in
PFS, the entire molecular process warrants further
analysis in the light of drug mechanism of action of
cisplatin and paclitaxel.
The cisplatin MoA molecular model holds 474 mo-
lecular features organized in 17 molecular processes,
respective numbers for the paclitaxel MoA molecular
model are 268 molecular features in 13 molecular pro-
cesses (Fig. 3a, b).
39 nodes of the cisplatin MoA molecular model are also
part of the HGSOCr molecular process 4, and 25 nodes
are shared by the paclitaxel MoA molecular model and
A B
Fig. 2 HGSOCr molecular model. a Each node represents a molecular process, the node diameter scales with the number of protein coding
genes included. Edges between molecular processes indicate a significant number of protein-protein interactions between protein coding genes
across molecular processes. Color-coding scales with the sum of individual biomarker frequencies in LASSO selection based on bootstrap runs of
the transcript feature set classifier for explaining variance in PFS. b Subgraph representation of molecular process 4. Each node codes for a protein
coding gene, edges represent interactions according to the underlying interaction network. Genes of specific relevance are highlighted in red
(VEGFA, mTOR, CCND1)
Andorfer et al. BMC Systems Biology  (2016) 10:33 Page 6 of 12
the HGSOCr molecular process 4. In total 43 of the 95
HGSOCr molecular process 4 members are either in the
cisplatin and/or the paclitaxel MoA molecular model,
resulting with respect to model sizes in a highly significant
overlap according to a Chi2 test. Apparently, drug mech-
anism of action and association with relapse are linked in
molecular process 4 of the HGSOCr molecular model.
The overlapping features resemble several genes reported
to be involved in drug resistance including ABC trans-
porters, the serine/threonine kinase mTOR, the apoptosis
inhibitor BCL2, the vascular endothelial growth factor A
(VEGFA), members of the STAT family, IL6 and tumor
necrosis factor alpha (TNF).
Computing KEGG pathway enrichment for the set of 95
protein coding genes in HGSOCr process 4 results in
eleven significantly enriched pathways as listed in Table 3.
Five of these KEGG pathways are also significantly enriched
on the basis of the 43 protein coding genes showing overlap
with the two drug mechanism of action molecular models
of cisplatin and paclitaxel.
Four signaling pathways are among the five pathways,
namely TGF-beta, mTOR, Jak-STAT, and Neurotrophin
signaling. With two features of the prognosis classifier
attributable to mTOR signaling (IGF1 and PTEN) spe-
cific focus is on the mTOR pathway as link with drug re-
sistance and relapse.
Regulation of the mTOR pathway and synthetic lethal
interactions
For evaluating relevance of the mTOR pathway with re-
spect to relapse, correlation with expression values of
mTOR pathway members in the TX-FERRISS data set is
Table 2 Clinical characteristics of samples and classifier performance
TX-TOTHILL TX-YOSHIHARA
Training set Test set
number of patients 145 71
no relapse > 22 months (sensitive) 63 42
relapse < 12 months (resistant) 82 29
average PFS 21.69 +/− 21.47 25.86 +/− 21.68
PFS, sensitive group 39.33 +/− 22.40 40.21 +/− 16.72
PFS, resistant group 8.13 +/− 2.77 5.07 +/− 3.09
FIGO stage
early stage (I-IIA) 15 0
advanced stage (IIB-IV) 130 71
Chemotherapy
platinum-based drug 29 0
platinum-based drug and taxanes 116 71
array platform Affymetrix Human Genome U133 Plus 2.0 Agilent Whole Human Genome Microarray 4x44K
optimism corrected AUC 0.786 0.721
Clinical characteristics of the patient samples used in transcriptomics profiling and performance of the prognostic transcript panel classifier in identifying sensitive
and resistant specimens
A B C
Fig. 3 Drug mechanism of action molecular models. Molecular model representation of (a) cisplatin, (b) paclitaxel, and (c) sirolimus mechanism
of action. Each node represents a molecular process, the node diameter scales with the number of protein coding genes included. Edges
between molecular processes indicate a significant number of protein-protein interactions between protein coding genes across molecular pro-
cesses. Color-coding scales with number of overlapping nodes with respect to nodes embedded in molecular process 4 of the HGSOCr
molecular model
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determined. Eleven mTOR pathway members show cor-
relation coefficients regarding PFS of > = 0.4 or < = −0.4,
with expression of seven genes being negatively corre-
lated and four being positively correlated with PFS
(Table 4). VEGFA shows the strongest correlation to PFS
with a Pearson R of −0.57 thus indicating higher levels
of VEGFA in patients with reduced PFS. Next to
VEGFA, the hypoxia inducible factor 1 alpha is nega-
tively correlated with PFS, being activated by mTOR and
itself being an activator of VEGFA.
Apparent involvement of the mTOR pathway in drug
resistance provides a rationale for evaluating mTOR in-
hibitors, selecting sirolimus as example. According to
molecular model interference of HGSOCr process unit 4
and a sirolimus MoA molecular model (Fig. 3c), highly
significant overlap is seen. 17 nodes of the sirolimus
MoA molecular model see matches in molecular process
4, next to covering key elements of the mTOR pathway
as such also addressing ErbB- and neutrophin-signaling
as well as ABC transporters.
Next to directly addressing the mTOR context via
sirolimus in relation to cisplatin and paclitaxel
mechanism of action, synthetic lethal interactions in-
duced by such drug combination may add to efficacy
in tackling resistance. Specifically, such effect may be
targeted to drug resistant cells potentially limiting
toxic effects of such triple drug combination in non-
cancer cells.
According to molecular model interference cisplatin
holds 39 nodes in the HGSOCr molecular process 4, the
respective numbers for paclitaxel and sirolimus are 25
and 17. Screening for synthetic lethal candidate interac-
tions among such molecular process 4 members identi-
fies a coupling of sirolimus and paclitaxel, involving a
protein kinase C (PRKCH) and the synthetic lethal
partners cyclin D1 (CCND1) and a second protein kin-
ase C (PRKCI).
A predictive biomarker for patient stratification
Biomarkers in their definition allow probing the status of
a specific molecular process, in the given focus ideally
informing on the mTOR pathway specifically at the inter-
face of platinum-based drug and taxane mechanism of
action. VEGFA exhibits strongest correlation with PFS, is
embedded in molecular process 4 of the HGSOCr mo-
lecular model, directly linked with the mTOR pathway,
and embedded in both, the cisplatin as well as paclitaxel
MoA molecular model. On top, the candidate is secreted
Table 3 KEGG pathway enrichment
Pathway # Genes Estimate p-value
hsa04350:TGF-beta signaling pathway 11 11.58 1.00E-05
hsa03010:Ribosome 11 11.58 1.00E-05
hsa04150:mTOR signaling pathway 8 8.42 1.04E-04
hsa02010:ABC transporters 7 7.37 3.36E-04
hsa04630:Jak-STAT signaling pathway 9 9.47 0.00901
hsa04620:Toll-like receptor signaling pathway 7 7.37 0.01620
hsa04010:MAPK signaling pathway 11 11.58 0.01982
hsa04914:Progesterone-mediated oocyte maturation 6 6.32 0.03358
hsa04012:ErbB signaling pathway 6 6.32 0.03330
hsa04722:Neurotrophin signaling pathway 7 7.37 0.03265
hsa04060:Cytokine-cytokine receptor interaction 10 10.53 0.04148
Pathways according to KEGG computed as significantly enriched in molecular process 4 of the HGSOCr molecular model. Pathways given in bold are further
identified as enriched in the drug mechanism of action model overlap feature set of cisplatin and paclitaxel matching with molecular process 4 members of the
HGSOCr molecular model
Table 4 Correlation of mTOR members to progression free survival
Affymetrix transcript ID (Affymetrix Human
















Pearson R correlation (> = 0.4 and < = −0.4) of mTOR members regarding PFS.
Provided are gene symbols, Affymetrix transcript IDs of the TX-
FERRISS dataset, and Pearson correlation coefficients
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and measurable in circulation, hence allowing minimally
invasive evaluation in patient samples.
Discussion
A major challenge in clinical management of ovarian
cancer is development of resistance against first line
therapy, in consequence leading to tumor relapse in the
majority of cases. We in this work present a data inte-
gration workflow for identifying relevant molecular pro-
cesses characterizing drug resistance in HGSOC with
respect to first line chemotherapy, from there linking
with alternative drug mechanism of action and candidate
predictive biomarkers.
Utilizing a molecular network approach allows deriv-
ing a molecular model approximating key molecular
context of the drug resistant phenotype, composed of 24
molecular processes in total embedding 409 protein
coding genes. Relating molecular processes to PFS via a
biomarker panel-based classifier gives rise to further
analyze a specific molecular process holding in total 95
molecular features. Functional characterization of this
gene set provides individual mediators of drug resistance
as ABC transporters, but also specific signaling path-
ways, namely TGF-beta, mTOR, JAK-STAT and Neutro-
phin signaling. These pathways are of specific interest,
being not only embedded in the HGSOCr molecular
model but also in the molecular mechanism of action
models of cisplatin and paclitaxel - against which resist-
ance developed in the first place.
Up to now tackling individual resistance mediators as
ABC transporters failed in clinical testing, e.g. seeing in-
creased toxicity and unexpected alterations in the
pharmacokinetics of antineoplastic drugs when adminis-
tered together with ABC inhibitors [31]. These findings
may point towards alternatively addressing signaling
pathways for overcoming drug resistance. With respect
to the specific signaling pathways identified in molecular
process 4 of the HGSOCr molecular model, involvement
in cancer progression and drug resistance is a common
theme. TGF-beta signaling carries out a dual role during
the progression of cancer. One of its key functions is to
maintain homeostasis of several cell types like epithelial,
endothelial, and hematopoietic cells, therefore acting as
tumor suppressor in the early stages of cancer through
the induction of cell cycle arrest and apoptosis [32].
Later in cancer development, due to oncogenic muta-
tions in this pathway, TFG-beta becomes capable of pro-
moting tumor growth and metastatic functions via
epithelial to mesenchymal transition induction. This
transition promotes cell migration and invasiveness, and
is considered a key step in the acquisition of resistance
to chemotherapeutic agents [33].
The JAK/STAT pathway is a crucial mediator of the
cellular responses to cytokines and growth factors and
involved in the regulation of cellular processes such as
cell growth, differentiation, apoptosis, development, and
immune response [34]. Not surprisingly it is found to be
altered in several cancer types and involved in drug re-
sistance and invasiveness [34]. STAT3, robustly activated
by interleucin-6, is well studied for promoting tumor
progression and poor prognosis [35].
The closely related family of neurotrophins is involved
in the survival, development, and function of neurons.
Through the tropomyosin-related kinase (Trk) family of
tyrosine receptors (TrkA, TrkB, and TrkC) they modu-
late multiple signaling pathways through the activation
of proteins like PI3K, Ras, MAPK or NF-kB, rendering
neutrophins highly relevant in development of chemo-
therapy resistance [36]. Increased expression of Trks,
especially TrkB, and correlation to poor prognosis is
reported in a number of cancers including ovarian
cancer [37].
Specific attention is with the mTOR pathway, found to
be activated in about half of the high grade serous ovarian
cancer patients [38]. The pathway holds a central role in
conferring environmental signals to regulate growth and
homeostasis. mTOR itself is part of two large protein com-
plexes (mTORC1 and mTORC2). mTORC1 integrates
input from growth factors, extra- and intracellular stress,
oxygen and energy status and amino acid levels. Activation
is mainly triggered via regulation of its inhibitors TSC1/2
[39]. Oncogenic mutations in this pathway are, in contrast
to other ovarian cancer subtypes, rare in HGSOC. The
constitutive activation in ovarian cancer is a result of ampli-
fication of pathway components like PI3K subunits (p110),
AKT isoforms (AKT1, AKT2, or AKT3), or members of
the mTOR complexes (RICTOR, RAPTOR). Other factors
include deregulation of upstream receptor tyrosine ki-
nases (ERBB3, ERBB2, IGF1R, EGFR), or the cross-talk
with the Ras pathway through amplification of KRAS
or MAPK [40]. The consequences of an upregulated
PI3K/AKT/mTOR pathway are extended cell survival,
further reported as being involved in drug resistance
[41]. The levels of pPIK3CA and pAkt are correlated
with a decreased survival in ovarian cancer [42]. Muta-
tions in PIK3CA and loss of the tumor suppressor
PTEN are shown to initiate ovarian tumorgenesis in
mice, being reversible by PI3K/AKT/mTOR pathway
inhibition [43].
Analysis of drug mechanism of action molecular
models of cisplatin and paclitaxel on the background of
molecular processes characterizing resistant HGSOC re-
sults in a number of genes associated with mTOR
signaling including mTOR itself, but also IGF1, VEGFA,
or MAPK1. Several studies support an increased activity
of the PI3K/AKT/mTOR pathway upon platinum or
paclitaxel based treatment. In in-vitro studies of ovarian
cancer cells, cisplatin addition leads to AKT
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phosphorylation and AKT/mTOR pathway induction.
Cisplatin resistant cells generated by sustained drug ex-
posure result in elevated levels of AKT/mTOR pathway
components [44]. The same is observed in colon and
cervical cancer cells. Cisplatin administration leads to
AKT1, mTOR, S6K, and 4E-BP1 phosphorylation and
hence pathway activation [45, 46]. The clear cell carcin-
oma subtype, in contrast to serous adenocarcinomas,
shows a response rate of only around 11 % to standard
first line therapy indicating an intrinsic drug resistance.
Interestingly in about 87 % of 52 tested clear cell carcin-
omas elevated mTOR activity is observed [47]. Inhib-
ition of the mTOR pathway, in most cases through PI3K
inhibitors, could sensitize the cells to cisplatin [46, 47].
Paclitaxel is found to activate the mTOR pathway in
cervical cancer cell lines and its inhibition sensitizes the
cells to treatment [48]. Also in an ovarian cancer cell
line as well as in xenograft models impeded mTOR
pathway activity increases the efficacy of paclitaxel [49].
A study addressing the synergistic effect of sirolimus
with cisplatin, paclitaxel, gemcitabine, or etoposide in
different ovarian cancer cell lines reveals a cell line
dependent response, however, seeing agonistic as well as
antagonistic effects [50]. These findings pinpoint two
essential elements to be considered when targeting the
mTOR pathway. First it is pivotal to utilize a suitable
biomarker to identify effective activity of the pathway.
As evidenced in different ovarian cancer cell lines and as
noted before also in human tissue samples mTOR path-
way activation is not an ubiquitous finding in ovarian
cancer drug resistance, hence stratification via a bio-
marker is necessary. Second, target specificity of the
drug needs consideration, as sirolimus for example only
targets the mTORC1 but not the mTORC2 complex, the
latter triggering a positive feedback on Akt [51].
Screening members of the mTOR pathway in a tran-
scriptomics dataset for exhibiting correlation with pro-
gression free survival reveals several candidates. Activators
of mTOR including PIK3CB, AKT3, or RHEB are upregu-
lated, suppressors as STK11 are downregulated with
respect to earlier relapse. RICTOR, a mTORC2 complex
member, is also identified as upregulated, and reported as
associated with cisplatin resistance through the inhibition
of AKT degradation in ovarian cancer cells, and respective
downregulation sensitized cells to cisplatin [52]. Addition-
ally, several targets of mTOR are found to be negatively
correlated with PFS including HIF1A and downstream
VEGFA and DDIT4. Interestingly EIF4E, upregulated by
mTOR, is found positively correlated with PFS.
VEGFA shows the strongest correlation with progres-
sion free survival and also its activator HIF1A exhibits a
significant upregulation upon early relapse. Several stud-
ies reveal a connection between the HIF1A/VEGFA axis
in drug resistance and poor prognosis in various cancer
types including ovarian carcinoma [53, 54]. Tumor de-
velopment usually involves a hypoxic state sensed by the
mTOR pathway leading to an activation of the hypoxia-
inducible factor 1 alpha (HIF1A) to facilitate angiogen-
esis upon VEGFA induction [55]. VEGFA abundance not
only shows the strongest correlation with PFS in our
analysis but also fulfils criteria to qualify as a biomarker,
namely being secreted and detectable in blood. A very
recent study in high grade serous ovarian carcinoma
documented the correlation of VEGFA levels and poor
prognosis, rendering VEGFA an ideal candidate to strat-
ify patients prone to drug resistance upon mTOR path-
way upregulation [56].
Several clinical trials have been performed in ovarian
cancer patients targeting the mTOR pathway, including
monotherapies as well as combination with standard
first line therapy, however, resulting in limited benefit
[40]. Data from a phase 2 trial of temsirolimus in persistent
and recurrent epithelial ovarian and primary peritoneal
malignancies showed only modest efficacy in unselected pa-
tients and the study authors concluded that only with the
inclusion of patient stratification markers further studies
are warranted [57].
In recent years inhibitors of PI3K/Akt and anti-
angiogenics as e.g. bevacizumab addressing VEGF have
received attention for allowing a more effective inhib-
ition of signal transduction in the pathway [40, 58], fur-
ther combined with mTOR inhibitors for achieving a
comprehensive inactivation of the mTOR pathway [59].
These strategies aim at interfering with compensatory
feedback loops, like the Akt activation via mTORC2
when mTORC1 is inhibited by rapalogs, or the activa-
tion of the insulin growth factor 1 receptor when its
inhibitor mTOR is blocked [60]. Also the cross talk to
other pathways like the RAS/MAPK cascade may coun-
teract drug effect through Erk1/2 activation upon
mTOR inhibition [61]. A further strategy follows dual
mTORC1/mTORC2 inhibitors, with preclinical data
demonstrating inhibition of ovarian cancer cell prolifer-
ation specifically when combined with paclitaxel [62].
Here synthetic lethal interactions may add to efficacy,
including CCND1 as well as PRKCI, both associated
with poor prognosis [63, 64]. Specifically cyclin D1 ap-
pears relevant, being proposed as selection marker for
mTOR inhibitor treatment according to phase II study
results [57].
Conclusions
Integrating molecular data characterizing drug resist-
ant HGSOC in a molecular process model identifies
the mTOR pathway as relevant component mediating
resistance in the context of cisplatin and paclitaxel
drug mechanism of action, and proposes mTOR inhib-
itors as means for addressing resistant phenotypes.
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Clinical trials following such approach identified mod-
est activity, clearly addressing the need for stratifica-
tion markers. VEGFA as well as cyclin D1 result as
candidate biomarkers for stratification, and combined
with dual mTOR inhibitors warrant further experi-
mental testing.
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